Finance

Lists
MESO:NASDAQ
Mesoblast Ltd
13,27 $
+1,30%
(+0,17) 1D
13 նոյ, 16:00:01 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MESO...
Open
13,13 $
High
13,28 $
Low
12,88 $
Mkt. cap
1,75 մլրդ
Avg. vol.
276,86 հզր
Volume
347,02 հզր
52-wk high
21,50 $
52-wk low
11,89 $
EPS
-0,44 $
Beta
2,21
Shares outstanding
130,13 մլն
No. of employees
108
Open
13,13 $
High
13,28 $
Low
12,88 $
Mkt. cap
1,75 մլրդ
Avg. vol.
276,86 հզր
Volume
347,02 հզր
52-wk high
21,50 $
52-wk low
11,89 $
EPS
-0,44 $
Beta
2,21
Shares outstanding
130,13 մլն
No. of employees
108
News stories
From web sources and news partners
Profile
Mesoblast Limited is an Australian regenerative medicine company. It seeks to provide treatments for inflammatory ailments, cardiovascular disease, and back pain. The company is led by Silviu Itescu, who founded the company in 2004. Wikipedia
About Mesoblast Ltd
CEOSilviu Itescu
Employees108
Founded2004
Headquarters-
SectorHealth Care
Industry-
Analyst ratings
Based on 2 analysts giving stock ratings to MESO in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for MESO in the last 3 months.
Highest
Current 13,27 $
39,00 $ (+193,90%)
Average
37,00 $ (+178,82%)
Lowest
35,00 $ (+163,75%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason McCarthy
Maxim Group
Buy
Maintained
35,00 $
+163,8%
09/24/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
39,00 $
+193,9%
08/27/2026
Last report
29 հնվ, 2026 թ.
Fiscal period
Q2 2026
- / -0,03 A$
Revenue / Est. (AUD)
42,92 մլն / 34,76 մլն
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in AUD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
25,67 մլն
25,67 մլն
34,45 մլն
34,45 մլն
Cost of goods sold
26,88 մլն
26,88 մլն
-14,87 մլն
-14,87 մլն
Cost of revenue
26,88 մլն
26,88 մլն
-14,87 մլն
-14,87 մլն
Research and development expenses
-
-
45,07 մլն
45,07 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
14,27 մլն
14,27 մլն
14,40 մլն
14,40 մլն
Operating expense
12,95 մլն
12,95 մլն
60,79 մլն
60,79 մլն
Total operating expenses
39,83 մլն
39,83 մլն
45,92 մլն
45,92 մլն
Operating income
-14,16 մլն
-14,16 մլն
-11,47 մլն
-11,47 մլն
Other non operating income
-4,16 մլն
-4,16 մլն
2,61 մլն
2,61 մլն
EBT including unusual items
-19,86 մլն
-19,86 մլն
-8,58 մլն
-8,58 մլն
EBT excluding unusual items
-23,68 մլն
-23,68 մլն
-10,94 մլն
-10,94 մլն
Income tax expense
222,50 հզր
222,50 հզր
84,00 հզր
84,00 հզր
Effective tax rate
-1,12%
-1,12%
-0,98%
-0,98%
Other operating expenses
-1,32 մլն
-1,32 մլն
1,31 մլն
1,31 մլն
Net income
-20,08 մլն
-20,08 մլն
-8,67 մլն
-8,67 մլն
Net profit margin
-78,22%
-78,22%
-25,16%
-25,16%
Earnings per share
-
-
-
-
Interest and investment income
-
-
1,96 մլն
1,96 մլն
Interest expense
-5,64 մլն
-5,64 մլն
-4,29 մլն
-4,29 մլն
Net interest expenses
-5,64 մլն
-5,64 մլն
-2,34 մլն
-2,34 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-12,53 մլն
-12,53 մլն
-9,77 մլն
-9,77 մլն
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google Apps